Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | GSK3A | P49840 | 2/20 | 0.51 |
| ▸ | GSK3B | P49841 | 2/20 | 0.51 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.51 |
| ▸ | PDE4A | P27815 | 1/20 | 0.48 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.48 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.47 |
| ▸ | CDK4 | P11802 | 2/20 | 0.46 |
| ▸ | CCND1 | P24385 | 2/20 | 0.46 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.46 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.46 |
| ▸ | CDK2 | P24941 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2886126 | 0.90 | GSK3A (0.52) | KDM4EALDH1A1NPC1GSK3AGSK3B | |
| SCHEMBL7370355 | 0.86 | PDE4A (0.48) | KDM4EALDH1A1NPC1GSK3AGSK3B | |
| SCHEMBL7369415 | 0.85 | ATM (0.49) | KDM4EALDH1A1HPGDMAPK1ROCK1 | |
| SCHEMBL1251253 | 0.83 | NPSR1 (0.67) | KDM4EALDH1A1NPC1HPGDROCK1 | |
| SCHEMBL30719652 | 0.83 | ATM (0.67) | KDM4EALDH1A1NPC1GSK3AGSK3B | |
| SCHEMBL710318 | 0.83 | ATM (0.67) | KDM4EALDH1A1NPC1GSK3AGSK3B | |
| SCHEMBL7364011 | 0.82 | MAPK1 (0.73) | KDM4EALDH1A1HPGDMAPK1ROCK1 | |
| SCHEMBL1251585 | 0.81 | NPSR1 (0.51) | KDM4EALDH1A1MAPK1ROCK1ATM | |
| SCHEMBL7360223 | 0.78 | MAP2K4 (0.56) | KDM4EMAPK1ROCK1ATMNPSR1 | |
| SCHEMBL7367837 | 0.77 | MAP2K4 (0.52) | KDM4EMAPK1ROCK1ATMNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7645756-B2 | 6-[4-(3-piperidin-1-ylpropoxy)-phenyl]-[1,2,4]triazolo[4,3-b]pyridazine; has histamine-H3 receptor antagonistic effect or a histamine-H3 receptor inverse-agonistic effect; for metabolic system, circulatory system or nervous system diseases | BANYU PHARMACEUTICAL CO. LTD. (JP) | 2010-01-12 | — | — | US | disclosed |
| US-20070167453-A1 | Nitrogenous fused heteroaromatic ring derivative | MSD K.K. (JP) | 2007-07-19 | — | — | US | disclosed |
| EP-1719756-A1 | NITROGENOUS FUSED HETEROAROMATIC RING DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-08 | — | — | EP | disclosed |
| EP-0612321-A1 | PYRIDO PYRIDAZINONE AND PYRIDAZINTHIONE COMPOUNDS WITH PDE IV INHIBITING ACTIVITY | SYNTEX (U.S.A.) INC. (US) | 1994-08-31 | — | — | EP | disclosed |
| WO-1993007146-A1 | BENZO AND PYRIDO PYRIDAZINONE AND PYRIDAZINTHIONE COMPOUNDS WITH PDE IV INHIBITING ACTIVITY | SYNTEX (U.S.A.) INC. (US) | 1993-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167453-A1 | Nitrogenous fused heteroaromatic ring derivative | HRH3, HRH2, HRH4 | KDM4E 4024/4885ALDH1A1 1934/4885NPC1 2186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.